Showing 2441-2450 of 7613 results for "".
A Tale of Two Toxins
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-tale-of-two-toxins/22074/From a recent approval to a late-stage candidate, the field is evolving. Experts weigh in on the latest.New OTC Topicals Target Hyperpigmentation, Melasma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-otc-topicals-target-hyperpigmentation-melasma/22081/There's a new and expanding menu of options to improve uneven tone, proving that OTCs can provide benefit for a vexing concern.Protecting Your Most Valuable Asset: Insurance
https://practicaldermatology.com/topics/practice-management/protecting-your-most-valuable-asset-insurance/20817/A refresher on what you need to know about term life, permanent (cash value) life, and disability insurance.2018 Therapeutics and Device Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2018-therapeutics-and-device-highlights/18374/2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.Where are You Getting Your Asset Protection Advice?
https://practicaldermatology.com/topics/practice-management/where-are-you-getting-your-asset-protection-advice/20344/Your CPA may be mistaken.Flower Power: Inside Growing Interest in Topical Botanicals
https://practicaldermatology.com/topics/practice-management/flower-power-inside-growing-interest-in-topical-botanicals/20524/Botanicals are cropping up in growing numbers of skincare products. Are you ready to field patient questions?New NMSC Guidelines Highlight Options and Need for More Research
https://practicaldermatology.com/topics/practice-management/new-nmsc-guidelines-highlight-options-and-need-for-more-research/20544/The latest guidelines of care for SCC and BCC endorse the standard of care and show we need additional, high-quality research into non-surgical options.Therapeutics Update: Notable Approvals in 2017
https://practicaldermatology.com/topics/skin-cancer-photoprotection/therapeutics-update-notable-approvals-in-2017/20398/A look at the newest additions to the medicine chest.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sThe Menassaince
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-menassaince/18722/Men are an increasingly important demographic in aesthetics today, Steven Dayan, MD tells Dermtube host Joel Cohen, MD. Unlike their female counterparts, men tend to prefer one-and-done procedures and often seek treatment after hours, he says.